CD274 and neoplasm: Blocking CDK4/6 with inhibitors increases PD-L1 levels, enhancing immune suppression, which suggest that combining CDK4/6 inhibitors with PD-1/PD-L1 immunotherapies could disrupt tumor immune evasion and improve patient outcomes (Zhang et al., 2018).